NRX Pharmaceuticals (NRXP) Net Cash Flow Growth (3y) (2020 - 2026)
NRX Pharmaceuticals (NRXP) Net Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 475.46 Bn | 470.67 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.19 Bn | 115.94 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.44 Bn | 60.69 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.20 Bn | 63.20 Bn | - | - |
| 8 | Argenx Se | 57.08 Bn | 51.90 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.11 Bn | 38.11 Bn | - | - |
| 10 | NRX Pharmaceuticals | 124.13 Mn | 117.43 Mn | 437,000.00 | 32.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.54% |
| Dec 31, 2025 | -29.78% |
| Sep 30, 2025 | 45.58% |
| Jun 30, 2025 | 44.76% |
| Mar 31, 2025 | -31.19% |
| Dec 31, 2024 | 73.79% |
| Sep 30, 2024 | -26.20% |
| Jun 30, 2024 | 71.39% |
| Mar 31, 2024 | -31.75% |
| Dec 31, 2023 | 44.82% |
| Sep 30, 2023 | -129.87% |
| Jun 30, 2023 | -27.22% |
| Mar 31, 2023 | -258.12% |
| Dec 31, 2022 | 124.34% |
| Sep 30, 2022 | -226.03% |
| Jun 30, 2022 | -3,229.81% |
| Mar 31, 2022 | 1,008.53% |
| Sep 30, 2021 | 313.09% |
| Jun 30, 2021 | 33.35% |
| Mar 31, 2021 | 301.33% |